Jpmorgan Chase & CO Harvard Bioscience Inc Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 18,104 shares of HBIO stock, worth $42,906. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,104
Previous 16,714
8.32%
Holding current value
$42,906
Previous $70,000
27.14%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding HBIO
# of Institutions
106Shares Held
32MCall Options Held
1.2KPut Options Held
1.2K-
Black Rock Inc. New York, NY2.84MShares$6.74 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN2.77MShares$6.57 Million0.49% of portfolio
-
Harvey Partners, LLC Tarrytown, NY2.56MShares$6.06 Million0.9% of portfolio
-
Amh Equity LTD2.2MShares$5.21 Million8.75% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.12MShares$5.02 Million0.0% of portfolio
About HARVARD BIOSCIENCE INC
- Ticker HBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 41,636,500
- Market Cap $98.7M
- Description
- Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...